摩根士丹利发表研究报告,对内地医药股最新评级及目标价表列如下:股份|投资评级|目标价(港元)相关内容《大行》富瑞降药明生物(02269.HK)目标价至42元 评级「买入」创新药/生物科技类首选翰森制药(03692.HK) +0.080 (+0.449%) 沽空 $1.27千万; 比率 41.222% |增持|50元信达生物(01801.HK) +0.100 (+0.253%) 沽空 $1.39千万; 比率 12.187% |增持|64─>104元药明生物(02269.HK) +0.380 (+2.687%) 沽空 $2.48千万; 比率 1.687% |增持|91.5─>130元---------------------------三生制药(01530.HK) -0.020 (-0.301%) 沽空 $25.43万; 比率 0.915% |增持|12元康方生物-B(09926.HK) +0.250 (+0.508%) 沽空 $6.27百万; 比率 9.266% |增持|43.5元康宁杰瑞制药-B(09966.HK) +0.030 (+0.577%) 沽空 $78.58万; 比率 8.781% |增持|20元歌礼制药-B(01672.HK) -0.040 (-2.797%) |与大市同步|3元康希诺生物-B(06185.HK) +0.800 (+3.912%) 沽空 $30.18万; 比率 0.762% |增持|210─>242元石药集团(01093.HK) -0.110 (-1.603%) 沽空 $2.79千万; 比率 31.173% |增持|12.8─>11.6元基石药业-B(02616.HK) +0.040 (+3.704%) |增持|14元诺诚健华-B(09969.HK) -0.010 (-0.194%) 沽空 $57.19万; 比率 2.847% |增持|17.5元李氏大药厂(00950.HK) +0.010 (+0.870%) |增持|8元欧康维视生物(01477.HK) -0.010 (-0.143%) 沽空 $12.86万; 比率 3.742% |增持|36元荣昌生物-B(09995.HK) -0.700 (-2.244%) 沽空 $30.01万; 比率 1.899% |增持|83元中生制药(01177.HK) +0.010 (+0.327%) 沽空 $9.86百万; 比率 21.291% |增持|9.87─>10元研发及服务药明康德(02359.HK) +1.800 (+4.523%) 沽空 $1.76千万; 比率 2.868% |增持|155元互联网医药阿里健康(00241.HK) +0.010 (+0.313%) 沽空 $1.76千万; 比率 17.113% |增持|26元平安好医生(01833.HK) +0.040 (+0.328%) 沽空 $9.50百万; 比率 21.717% |增持|124─>108元相关内容《大行》大摩降信达生物(01801.HK)目标价至66.5元 康诺亚-B(02162.HK)下调至50元医疗设备微创医疗(00853.HK) +0.190 (+2.714%) 沽空 $1.28百万; 比率 2.862% |增持|20.5元沛嘉医疗-B(09996.HK) 0.000 (0.000%) |增持|33.6元威高股份(01066.HK) +0.010 (+0.187%) 沽空 $1.57百万; 比率 7.830% |与大市同步|17元药厂康哲药业(00867.HK) +0.020 (+0.267%) 沽空 $8.70百万; 比率 12.977% |增持|12.5元复星医药(02196.HK) +0.060 (+0.446%) 沽空 $2.63百万; 比率 8.668% |增持|41.8元东阳光药(01558.HK) -0.120 (-0.987%) 沽空 $48.83万; 比率 3.050% |增持|15.1元丽珠医药(01513.HK) +0.150 (+0.508%) 沽空 $37.48万; 比率 11.483% |与大市同步|34.6元绿叶制药(02186.HK) -0.050 (-1.639%) 沽空 $60.44万; 比率 2.801% |与大市同步|3.8元先声药业(02096.HK) -0.090 (-1.554%) 沽空 $13.33万; 比率 0.753% |增持|13元石四药集团(02005.HK) -0.110 (-2.187%) 沽空 $11.90万; 比率 4.934% |增持|6.6元联邦制药(03933.HK) -0.080 (-0.771%) 沽空 $4.16万; 比率 0.251% |与大市同步|7.9元医药分销商华润医药(03320.HK) -0.020 (-0.321%) 沽空 $4.17百万; 比率 9.788% |与大市同步|4.8元上海医药(02607.HK) +0.280 (+2.295%) 沽空 $5.35百万; 比率 19.064% |增持|17.8元国药控股(01099.HK) +0.300 (+1.348%) 沽空 $1.43千万; 比率 14.712% |增持|28.1元相关内容《大行》瑞银降药明生物(02269.HK)目标价至16.6元 评级「中性」医院股华润医疗(01515.HK) +0.060 (+1.376%) 沽空 $49.82万; 比率 3.310% |增持|6.6元锦欣生殖(01951.HK) -0.010 (-0.310%) 沽空 $1.35千万; 比率 21.160% |增持|12─>14.6元原料药股海普瑞(09989.HK) 0.000 (0.000%) |增持|18.3元传统中药股同仁堂国药(03613.HK) +0.040 (+0.382%) 沽空 $2.30百万; 比率 16.027% |增持|11.9元中国中药(00570.HK) -0.020 (-0.465%) 沽空 $29.17万; 比率 1.918% |增持|4.7元白云山(00874.HK) +0.050 (+0.217%) 沽空 $78.67万; 比率 3.565% |与大市同步|21元神威药业(02877.HK) +0.140 (+1.436%) 沽空 $3.93万; 比率 1.242% |与大市同步|6.7元同仁堂科技(01666.HK) -0.070 (-1.197%) 沽空 $5.87万; 比率 1.484% |与大市同步|6.3元相关内容《大行》瑞银升诺诚健华(09969.HK)目标价至7.6元 首季业绩逊预期(da/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-14 12:25。)